India’s Cheaper Weight-Loss Drug Era Could Change the Fight Against Diabetes and Obesity

India may be entering a major new phase in the treatment of diabetes and obesity, with cheaper versions of semaglutide now expected to make a class of high-profile weight-loss and diabetes drugs far more accessible than before. After the expiry of Novo Nordisk’s semaglutide patent on March 20, several Indian drugmakers moved quickly to launch more affordable versions, potentially opening the door for many more patients who had previously been priced out of treatment.

That matters because India is carrying an enormous metabolic disease burden. According to the ICMR-INDIAB study cited in the report, about 101 million Indians are living with diabetes, 136 million with prediabetes, 254 million with generalised obesity, and 351 million with abdominal obesity. In that context, doctors see cheaper GLP-1 drugs not as a niche lifestyle product, but as a potentially important tool in tackling what many now call “diabesity” — the overlapping crisis of diabetes and obesity.

Until now, cost has been one of the biggest barriers. The article notes that branded versions such as Ozempic and Wegovy have typically cost around ₹8,000 to ₹16,000 or more, while oral semaglutide has been priced in the ₹2,300 to ₹3,300 range. By contrast, newly launched generic versions are reportedly being introduced at roughly ₹1,290 to ₹4,200 per month, which could make them 65 to 90 percent cheaper than earlier options. That kind of price shift could significantly widen access for Indian patients who need long-term treatment but have struggled to afford it.

Doctors quoted in the report say this could be a real turning point, but not a magic fix. Specialists from hospitals including BLK-MAX, Apollo, Max Healthcare, Sir Ganga Ram Hospital, Sir HN Reliance Hospital, and Meridian Hospital argue that lower prices may encourage more people to start or continue therapy, especially those who had stopped because of cost. At the same time, they stress that these medicines are not meant to be taken casually or driven by trends. They are prescription drugs that need proper medical evaluation, careful patient selection, and monitoring for side effects.

The article also makes an important point about awareness. Even as obesity and diabetes rise, public understanding of newer GLP-1 therapies remains limited. A Kantar report cited in the piece suggests awareness in urban India is still only around 4.99 percent. Experts say too many people still think in narrow terms — either “sugar control” or cosmetic weight loss — without fully understanding obesity as a chronic metabolic condition that can affect the heart, liver, kidneys, hormones, and overall long-term health.

That is why doctors say the conversation has to go beyond pills alone. Better treatment access must be matched by better education, earlier screening, and a broader understanding of metabolic health. People at risk — including those with family history, abdominal obesity, fatty liver, PCOS, gestational diabetes history, or sedentary lifestyles — need to be identified sooner. And treatment, experts say, should be seen as a spectrum that includes diet, exercise, sleep, behaviour change, medicines, and in some cases bariatric or metabolic surgery.

There is also a regulatory side to this shift. The article notes that Indian regulators have cautioned against direct or indirect public advertising of prescription weight-loss drugs, and experts agree that awareness campaigns must stay responsible and medically grounded. The aim, they suggest, should not be to create hype, but to improve understanding and reduce stigma around obesity and diabetes while helping patients make informed decisions with doctors.

In the end, the arrival of cheaper semaglutide in India could mark an important public health moment. It will not solve the country’s diabetes and obesity crisis on its own, and it is certainly not a miracle cure. But by lowering the affordability barrier, it may finally allow a much larger number of patients to access a treatment option that was once out of reach — and that could begin to reshape how India confronts one of its fastest-growing health challenges.

References

1. Financial Express. “India’s magic pill moment: How cheaper weight loss drugs will reshape fight against dia-besity.” Published March 2026. Available at: https://www.financialexpress.com/life/health/indias-magic-pill-moment-how-cheaper-weight-loss-drugs-will-reshape-fight-against-dia-besity/4179986/
2. Anjana RM et al. The Lancet Diabetes & Endocrinology. “Metabolic non-communicable disease health report of India.” This source supports the ICMR-INDIAB figures on diabetes, prediabetes, and obesity burden in India. Available at: https://www.thelancet.com/journals/landia/article/PIIS2213-8587%2823%2900119-5/fulltext